Alcor Responds to Court Order

PHOENIX, Dec. 3 -- Joe Waynick, chief executive officer for Alcor Life Extension Foundation Inc., announced today that the organization has received the Court's final order in the matter involving the release of the document of gift under the Arizona Anatomical Gift Act authorizing the cryopreservation of baseball legend, Ted Williams.

In the order dated November 30, 2004, Maricopa County Superior Court Judge Thomas Dunevant III, instructed Alcor to present the document of gift to Williams' nephews, Ted and Sam Williams.

According to Waynick, "Alcor complies with the Arizona Anatomical Gift Act and we have, and will continue, to vigorously defend the rights of our members and their families to choose cryopreservation. The Court's order is a victory for Alcor as it allows us to continue to provide uninterrupted service to our members and their families who properly comply with the requirements of the Arizona Anatomical Gift Act."

"As we have stated in the past, Alcor's policy is to comply with court rulings regarding the release of the document of gift of any Alcor patient, if ordered through proper legal channels," Waynick said. "We do reserve the right to exhaust our legal remedies and we will be reviewing the order with legal counsel to determine if any further action is required."

Waynick noted that Alcor was merely an ancillary third party in the legal dispute among family members over the disposition of Williams' body and that the Foundation was not accused of any wrongdoing. "Alcor was entitled to obtain a court determination concerning the requirements of the Arizona Anatomical Gift Act before releasing the document of gift," said Waynick. "The court order provides the necessary legal directive to release the document as required under this Act."

About Alcor Life Extension Inc.

The Alcor Life Extension Foundation, a nonprofit organization founded in 1972, is the world leader in cryonics, and cryonics research and technology. Cryonics is the science of using ultra-cold temperatures to suspend and preserve human life. The intent is that technologically advanced scientific procedures will one day be available to revive cryopreserved humans and restore them to good health.

The promise of cryopreservation has taken a quantum leap forward with the ongoing development of molecular nanotechnology and the introduction of vitrification to Alcor's protocols.

One use of nanotechnology is the expectation that cell-sized machines will be developed to repair damage or cure disease at the cellular level, including any potential damage that results from the cryopreservation processes.

Alcor performed its first human cryopreservation in 1976. Since then, Alcor has engaged in long-term patient care as well as cryopreservation procedures. Among Alcor's scientific achievements is the use of advanced cryoprotectant formulas capable of achieving ice-free preservation, known as vitrification.

Today, Alcor is the only full-service cryonics organization in existence. Alcor has more than 697 members from around the world and 67 patients in cryostasis. For more information about Alcor and cryonics, visit